CA2873404C - Membrane encapsulated nanoparticles and method of use - Google Patents

Membrane encapsulated nanoparticles and method of use Download PDF

Info

Publication number
CA2873404C
CA2873404C CA2873404A CA2873404A CA2873404C CA 2873404 C CA2873404 C CA 2873404C CA 2873404 A CA2873404 A CA 2873404A CA 2873404 A CA2873404 A CA 2873404A CA 2873404 C CA2873404 C CA 2873404C
Authority
CA
Canada
Prior art keywords
nanoparticle
cell
membrane
derived
plasma membrane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2873404A
Other languages
English (en)
French (fr)
Other versions
CA2873404A1 (en
Inventor
Liangfang Zhang
Ronnie Hongbo Fang
Che-ming HU (jack)
Jonathan COPP
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Publication of CA2873404A1 publication Critical patent/CA2873404A1/en
Application granted granted Critical
Publication of CA2873404C publication Critical patent/CA2873404C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/148—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5176—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Botany (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
CA2873404A 2011-06-02 2012-05-24 Membrane encapsulated nanoparticles and method of use Active CA2873404C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161492626P 2011-06-02 2011-06-02
US61/492,626 2011-06-02
PCT/US2012/039411 WO2013052167A2 (en) 2011-06-02 2012-05-24 Membrane encapsulated nanoparticles and method of use

Publications (2)

Publication Number Publication Date
CA2873404A1 CA2873404A1 (en) 2013-04-11
CA2873404C true CA2873404C (en) 2022-08-30

Family

ID=48044349

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2873404A Active CA2873404C (en) 2011-06-02 2012-05-24 Membrane encapsulated nanoparticles and method of use

Country Status (9)

Country Link
US (5) US12097290B2 (https=)
EP (2) EP3412282B1 (https=)
JP (1) JP6100762B2 (https=)
CN (2) CN103857387B (https=)
CA (1) CA2873404C (https=)
DK (1) DK2714017T3 (https=)
ES (1) ES2685333T3 (https=)
TW (2) TWI638667B (https=)
WO (1) WO2013052167A2 (https=)

Families Citing this family (179)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RU2013120302A (ru) 2010-10-01 2014-11-20 Модерна Терапьютикс, Инк. Сконструированные нуклеиновые кислоты и способы их применения
EP2691101A2 (en) 2011-03-31 2014-02-05 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
CN103857387B (zh) 2011-06-02 2017-03-15 加利福尼亚大学董事会 膜包封的纳米颗粒及使用方法
WO2012174173A2 (en) * 2011-06-13 2012-12-20 President And Fellows Of Harvard College Multi-color nanoscale imaging based on nanoparticle cathodoluminescence
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RU2648950C2 (ru) 2011-10-03 2018-04-02 Модерна Терапьютикс, Инк. Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение
CN104114572A (zh) 2011-12-16 2014-10-22 现代治疗公司 经修饰的核苷、核苷酸和核酸组合物
US9594008B2 (en) * 2012-01-17 2017-03-14 The Scripps Research Institute Preparation of specimen arrays on an EM grid
US9702795B2 (en) * 2012-01-17 2017-07-11 The Scripps Research Institute Apparatus and method for producing specimens for electron microscopy
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
AU2013243948A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins associated with human disease
SG11201406336YA (en) * 2012-04-03 2014-11-27 Reneuron Ltd Stem cell microparticles
WO2014081507A1 (en) 2012-11-26 2014-05-30 Moderna Therapeutics, Inc. Terminally modified rna
EP2971010B1 (en) 2013-03-14 2020-06-10 ModernaTX, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2014197622A2 (en) * 2013-06-04 2014-12-11 The Regents Of The University Of California Liver-mimetic device and method for simulation of hepatic function using such device
WO2015021390A2 (en) * 2013-08-08 2015-02-12 The Regents Of The University Of California Nanoparticles leverage biological membranes to target pathogens for disease treatment and diagnosis
GB201317887D0 (en) 2013-10-09 2013-11-20 Reneuron Ltd Product
US20160194625A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Chimeric polynucleotides
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
JP2016538829A (ja) 2013-10-03 2016-12-15 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 低密度リポタンパク質受容体をコードするポリヌクレオチド
WO2015084677A1 (en) 2013-12-02 2015-06-11 Arytha Biosciences, Llc Toxoid preparation and uses thereof
WO2015143295A2 (en) 2014-03-20 2015-09-24 The Regents Of The University Of California Hydrogel compositions containing toxin-absorbing or binding nanoparticles and uses thereof
SG10201912038TA (en) 2014-04-23 2020-02-27 Modernatx Inc Nucleic acid vaccines
US10117886B2 (en) 2014-05-30 2018-11-06 Hao Cheng Hyaluronidase and a low density second PEG layer on the surface of therapeutic-encapsulated nanoparticles to enhance nanoparticle diffusion and circulation
US11110127B2 (en) 2014-06-02 2021-09-07 Cellics Therapeutics, Inc. Use of nanoparticles coated with red blood cell membranes to treat hemolytic diseases and disorders
EP3169693B1 (en) 2014-07-16 2022-03-09 ModernaTX, Inc. Chimeric polynucleotides
WO2016014846A1 (en) 2014-07-23 2016-01-28 Moderna Therapeutics, Inc. Modified polynucleotides for the production of intrabodies
US12285472B2 (en) * 2014-08-20 2025-04-29 The Regents Of The University Of California Self-antigen displaying nanoparticles targeting auto-reactive immune factors and uses thereof
WO2016044483A1 (en) 2014-09-16 2016-03-24 The Regents Of The University Of California Method for fabrication of microwells for controlled formation of 3-dimensional multicellular-shapes
MX2017003903A (es) 2014-10-03 2017-09-15 Ntercept Llc Composiciones y metodos para inhibir la actividad biologica de biomoleculas solubles.
WO2016109306A1 (en) * 2015-01-02 2016-07-07 Cellics Therapeutics, Inc. Use of nanoparticles coated with red blood cell membranes to enable blood transfusion
KR101720851B1 (ko) * 2015-01-29 2017-03-28 포항공과대학교 산학협력단 세포의 지질막에서 유래된 나노소포체 및 이의 용도
CA2977397A1 (en) 2015-03-03 2016-09-09 Cureport, Inc. Dual loaded liposomal pharmaceutical formulations
CN107530283A (zh) 2015-03-03 2018-01-02 奎尔波特股份有限公司 组合脂质体药物制剂
WO2016153979A1 (en) 2015-03-20 2016-09-29 The Regents Of The University Of California Modulating antibacterial immunity via bacterial membrane-coated nanoparticles
US10835493B2 (en) * 2015-04-20 2020-11-17 Academia Sinica Platelet-like proteo-microparticles and method of using such in drug delivery
CN107530285B (zh) * 2015-04-29 2021-07-27 加利福尼亚大学董事会 使用纳米粒子解毒
CN104922671B (zh) * 2015-06-09 2017-12-08 深圳先进技术研究院 一种吲哚菁绿复合纳米颗粒及其制备方法和应用
US20180177727A1 (en) * 2015-06-10 2018-06-28 Board Of Regents, The University Of Texas System Use of exosomes for the treatment of disease
WO2016205010A1 (en) * 2015-06-19 2016-12-22 The Regents Of The University Of California Treating vasculature related diseases or disorders using nanoparticles
US11224577B2 (en) 2015-06-19 2022-01-18 The Regents Of The University Of California Treating infection by a platelet-targeting microbe using nanoparticles
IL256445B2 (en) * 2015-06-30 2023-03-01 Nanotics Llc Compositions and methods related to absorbent particles
US11491115B2 (en) * 2015-07-09 2022-11-08 The Board Of Regents Of The University Of Texas System Nanoparticles containing extracellular matrix for drug delivery
EP3324979B1 (en) 2015-07-21 2022-10-12 ModernaTX, Inc. Infectious disease vaccines
US11364292B2 (en) 2015-07-21 2022-06-21 Modernatx, Inc. CHIKV RNA vaccines
US10363226B2 (en) * 2015-08-12 2019-07-30 North Carolina State University Platelet membrane-coated drug delivery system
WO2017030929A1 (en) * 2015-08-14 2017-02-23 The Johns Hopkins University Decoy nanoparticles to disrupt cancer cell-stormal cell networks
EP4286012A3 (en) 2015-09-17 2024-05-29 ModernaTX, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
CA3002912A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Nucleic acid vaccines for varicella zoster virus (vzv)
US20180289792A1 (en) 2015-10-22 2018-10-11 ModernaTX. Inc. Sexually transmitted disease vaccines
EP3364950A4 (en) 2015-10-22 2019-10-23 ModernaTX, Inc. VACCINES AGAINST TROPICAL DISEASES
TW201729835A (zh) 2015-10-22 2017-09-01 現代公司 呼吸道病毒疫苗
WO2017087897A1 (en) * 2015-11-18 2017-05-26 Arytha Biosciences, Llc Processes and systems for preparing cellular or viral membranes and nanoparticles
HRP20220652T1 (hr) 2015-12-10 2022-06-24 Modernatx, Inc. Pripravci i postupci unosa terapijskih sredstava
HUE057877T2 (hu) 2015-12-22 2022-06-28 Modernatx Inc Vegyületek és készítmények terápiás szerek intracelluláris bejuttatására
RS63135B1 (sr) 2015-12-23 2022-05-31 Modernatx Inc Postupci upotrebe polinukleotida koji kodiraju ox40 ligand
US11696959B2 (en) 2015-12-31 2023-07-11 City Of Hope Nanoparticle-cell construct with platinum anti-cancer agent
WO2017120342A1 (en) * 2016-01-08 2017-07-13 The Regents Of The University Of California Cellular or viral membrane coated nanostructures and uses thereof
US20190241658A1 (en) 2016-01-10 2019-08-08 Modernatx, Inc. Therapeutic mRNAs encoding anti CTLA-4 antibodies
CN105497912A (zh) * 2016-01-21 2016-04-20 华东师范大学 红细胞膜包裹的酸敏感高分子前药纳米递药系统的制备方法及用途
CN105769818B (zh) * 2016-03-16 2019-03-01 华东师范大学 用于抗体药物递送的红细胞膜包裹的抗体纳米粒子及制备方法
WO2017172769A1 (en) * 2016-03-28 2017-10-05 The Johns Hopkins University Biomimetic anisotropic polymeric particles with naturally derived cell membranes for enhanced drug delivery
CN106362148B (zh) * 2016-09-12 2019-08-27 中南大学 一种普鲁士蓝纳米介晶细胞膜包覆修饰方法
US11564889B2 (en) 2016-09-29 2023-01-31 North Carolina State University Stem cell biomimetic microparticles
CN110114072A (zh) * 2016-11-02 2019-08-09 纳米珀特伊根公司 聚合物纳米颗粒
US11583504B2 (en) 2016-11-08 2023-02-21 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
WO2018089851A2 (en) 2016-11-11 2018-05-17 Modernatx, Inc. Influenza vaccine
CN106620684A (zh) * 2016-11-18 2017-05-10 上海交通大学医学院附属新华医院 一种泛耐药菌的纳米疫苗及其制备方法
WO2018107088A2 (en) 2016-12-08 2018-06-14 Modernatx, Inc. Respiratory virus nucleic acid vaccines
US11065345B2 (en) 2017-01-04 2021-07-20 Nanotics, Llc Methods for assembling scavenging particles
WO2018170245A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Broad spectrum influenza virus vaccine
US11045540B2 (en) 2017-03-15 2021-06-29 Modernatx, Inc. Varicella zoster virus (VZV) vaccine
US11752206B2 (en) 2017-03-15 2023-09-12 Modernatx, Inc. Herpes simplex virus vaccine
WO2018170322A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Crystal forms of amino lipids
EP3595713A4 (en) 2017-03-15 2021-01-13 ModernaTX, Inc. RESPIRATORY SYNCYTIAL VIRUS Vaccine
US11969506B2 (en) 2017-03-15 2024-04-30 Modernatx, Inc. Lipid nanoparticle formulation
SMT202300097T1 (it) 2017-03-15 2023-05-12 Modernatx Inc Composto e composizioni per il rilascio intracellulare di agenti terapeutici
CN108653236B (zh) 2017-03-31 2025-03-25 上海惠永药物研究有限公司 一种生物膜包载药物纳米晶体的制备方法及其用途
KR102581296B1 (ko) * 2017-04-21 2023-09-22 코스타 쎄라퓨틱스 인크. 막 지질 코팅된 나노입자 및 사용 방법
US12077501B2 (en) 2017-06-14 2024-09-03 Modernatx, Inc. Compounds and compositions for intracellular delivery of agents
US11786607B2 (en) 2017-06-15 2023-10-17 Modernatx, Inc. RNA formulations
US12433843B2 (en) * 2017-07-28 2025-10-07 National University Of Singapore Biomolecular composites comprising modified cell ghosts
WO2019046809A1 (en) 2017-08-31 2019-03-07 Modernatx, Inc. METHODS OF MANUFACTURING LIPID NANOPARTICLES
EP3681514A4 (en) 2017-09-14 2021-07-14 ModernaTX, Inc. RNA VACZINE AGAINST ZIKA VIRUS
US20210187018A1 (en) * 2017-12-07 2021-06-24 Flagship Pioneering Innovations V, Inc. Cytobiologics and therapeutic uses thereof
CN108066317B (zh) * 2017-12-19 2020-04-03 中南大学湘雅三医院 纳米药物控释体系的制备方法及其产品与应用
WO2019143637A1 (en) 2018-01-18 2019-07-25 Cellics Therapeutics, Inc. Methods and compositions for quantifying hemoglobin
WO2019148101A1 (en) 2018-01-29 2019-08-01 Modernatx, Inc. Rsv rna vaccines
CN108042510A (zh) * 2018-02-11 2018-05-18 复旦大学附属中山医院 一种靶向动脉粥样硬化斑块的血小板膜包被的雷帕霉素仿生纳米颗粒及其用途
US10842755B2 (en) 2018-03-23 2020-11-24 University Of South Carolina Nanoparticles for brain targeted drug delivery
AU2019251449A1 (en) * 2018-04-09 2020-11-12 Orgenesis Inc. Bioxomes particles, redoxomes, method and composition
CN108498805B (zh) * 2018-04-20 2021-04-09 中国科学院化学研究所 一种利用生物细胞膜提高阳离子共轭聚合物生物相容性的方法
WO2019227091A1 (en) * 2018-05-25 2019-11-28 The Penn State Research Foundation Nanoparticle for protein delivery
WO2019246014A1 (en) * 2018-06-18 2019-12-26 North Carolina State University Stem cell biomimetic nanoparticle therapeutic agents and uses thereof
EP3820509A1 (en) 2018-07-09 2021-05-19 Flagship Pioneering Innovations V, Inc. Fusosome compositions and uses thereof
US20210338583A1 (en) * 2018-07-23 2021-11-04 Robert B. Campbell Cell membrane lipid-extracted nanoparticles (clens) for selective targeting, image analysis and cancer therapy
US11096899B2 (en) * 2018-09-07 2021-08-24 Wisconsin Alumni Research Foundation Bacterial membrane nanoparticles as an immunotherapy system for cancer treatment
MA53650A (fr) 2018-09-19 2021-07-28 Modernatx Inc Lipides peg et leurs utilisations
AU2019345067A1 (en) 2018-09-19 2021-04-08 Modernatx, Inc. High-purity peg lipids and uses thereof
US12263248B2 (en) 2018-09-19 2025-04-01 Modernatx, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
CN113271926A (zh) 2018-09-20 2021-08-17 摩登纳特斯有限公司 脂质纳米颗粒的制备及其施用方法
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
WO2020080876A1 (ko) * 2018-10-18 2020-04-23 고려대학교 세종산학협력단 생체 물질 검출 센서 및 그 제조방법
US12496274B2 (en) 2018-11-14 2025-12-16 Flagship Pioneering Innovations V, Inc. Compositions and methods for compartment-specific cargo delivery
EP3883601A4 (en) * 2018-11-22 2022-07-20 Ramot at Tel-Aviv University Ltd. IMMUNOGENIC COMPOSITIONS WITH N-GLYCOLYLNEURAMINIC ACID CONTAINING NANOPARTICLES
CN111214439B (zh) * 2018-11-23 2023-02-10 复旦大学 一种具有细菌成孔毒素吸附性能的纳米药物系统及其用途
JP7518830B2 (ja) * 2018-11-26 2024-07-18 アリサ バイオサイエンシーズ エルエルシー 細胞膜を含有するナノ粒子およびその使用
EP3886911A4 (en) * 2018-11-28 2022-08-24 University of Delaware BIOMEMBRANE-COATED NANOPARTICLES (BIONPS) FOR DELIVERY OF DRUGS TO STEM CELLS
US10265017B1 (en) * 2018-12-12 2019-04-23 Lucas J. Myslinski Device, method and system for implementing a physical area network for cancer immunotherapy
US11351242B1 (en) 2019-02-12 2022-06-07 Modernatx, Inc. HMPV/hPIV3 mRNA vaccine composition
US12024709B2 (en) 2019-02-27 2024-07-02 Actym Therapeutics, Inc. Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
CN113748124A (zh) 2019-02-27 2021-12-03 阿克蒂姆治疗有限公司 工程化以定植肿瘤、肿瘤驻留免疫细胞和肿瘤微环境的免疫刺激性细菌
EP3938379A4 (en) 2019-03-15 2023-02-22 ModernaTX, Inc. Hiv rna vaccines
WO2020223454A1 (en) 2019-04-30 2020-11-05 The Regents Of The University Of California Broad-spectrum nanoparticle enabled genomic detection
CN111956947A (zh) * 2019-05-20 2020-11-20 安行生物技术有限公司 向细胞内递送纳米颗粒的方法和装置
AU2020287620B2 (en) * 2019-06-07 2025-12-18 President And Fellows Of Harvard College Compositions and methods relating to erythrocytes with adhered particles
CN110179769A (zh) * 2019-06-11 2019-08-30 北京大学深圳医院 一种可以诱导病灶部位局部免疫应答的微纳米粒子药物载体
CN110269847A (zh) * 2019-06-21 2019-09-24 温州医科大学 一种用于中和细菌毒素的仿生纳米材料及其制备方法与应用
CN110302369B (zh) * 2019-06-28 2022-04-29 中国人民解放军陆军军医大学 以壳聚糖修饰PLGA的大肠杆菌Vo外膜蛋白纳米粒疫苗及其制备方法和应用
AU2020315645A1 (en) * 2019-07-16 2022-02-17 Coastar Therapeutics Inc. Process of making membrane lipid coated nanoparticles
WO2021046033A1 (en) * 2019-09-03 2021-03-11 The Regents Of The University Of California Biomimetic nanoemulsions for oxygen delivery
EP4031582A4 (en) * 2019-09-18 2023-10-04 The Regents of the University of California IMMUNOACTIVE MICROPARTICLES AND ASSOCIATED USES
AU2020350759A1 (en) 2019-09-19 2022-03-31 Modernatx, Inc. Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents
BR112022004936A2 (pt) 2019-09-19 2022-06-14 Modernatx Inc Compostos lipídicos contendo carbonato e composições para distribuição intracelular de agentes terapêuticos
WO2021091582A1 (en) * 2019-11-08 2021-05-14 The Methodist Hospital Neurosome/astrosome compositions and methods of use
CA3107857A1 (en) * 2019-12-20 2021-06-20 Mcmaster University Hybrid biological membranes, methods of making and uses thereof
CN113041345B (zh) * 2019-12-26 2023-09-01 复旦大学 一种纳米类毒素疫苗及其用途
CN111111480B (zh) * 2020-01-09 2021-09-14 南京工业大学 一种唑来磷酸改性纳滤膜及其制备方法
WO2021150460A1 (en) 2020-01-20 2021-07-29 Arytha Biosciences Llc Devices containing cellular membrane and uses thereof
US20230083448A1 (en) * 2020-02-07 2023-03-16 The Johns Hopkins University Compositions of alum nanoparticles for immunomodulation and methods for producing the same
WO2021163455A1 (en) * 2020-02-14 2021-08-19 The Trustees Of Columbia University In The City Of New York Scalable and facile cell-membrane-coating technology for both positively and negatively charged particles
CN111265549B (zh) * 2020-03-02 2022-03-01 苏州大学 表面pd-l1分子过表达的间充质干细胞膜包被的仿生纳米颗粒及其制备和应用
US12083162B2 (en) * 2020-03-24 2024-09-10 The Regents Of The University Of California Universal nanosponge for treating respiratory viral infection
CN113679829B (zh) * 2020-05-18 2024-01-02 北京繁易纳维科技有限公司 一种预防癌症术后复发的肿瘤疫苗及其制备方法和应用
CN111603454A (zh) * 2020-06-08 2020-09-01 上海交通大学医学院附属第九人民医院 一种多重靶向的融合细胞膜修饰的仿生纳米递送系统及其制备方法与应用
WO2022020985A1 (zh) * 2020-07-27 2022-02-03 上海市公共卫生临床中心 利用呼吸道上皮细胞膜防治呼吸道传染病的方法及应用
CN113041356B (zh) * 2020-10-28 2022-07-22 湖南中医药大学 血筒素靶向载药体系、制备方法及其应用
EP4292589A4 (en) * 2020-12-07 2025-04-09 Fortuga Bio Dendritic cell-thickened nanostructure for use in cancer immunotherapy and manufacturing process therefor
US12041939B2 (en) 2020-12-08 2024-07-23 Cornell University Enzyme-loaded pollen-mimicking microparticles for organophosphate detoxification of insect pollinators
CN112730324B (zh) * 2020-12-17 2022-11-08 中山大学 基于量子点掺杂的pla纳米线共振散射折射率传感器
CN114762726A (zh) * 2021-01-15 2022-07-19 上海交通大学医学院附属仁济医院 抗原递呈细胞膜包裹的纳米颗粒及制备方法与应用
CN113209044A (zh) * 2021-01-29 2021-08-06 广州医科大学 靶向递送HDACIs的仿生纳米颗粒及其制备方法和应用
US11524023B2 (en) 2021-02-19 2022-12-13 Modernatx, Inc. Lipid nanoparticle compositions and methods of formulating the same
CN113244189A (zh) * 2021-02-22 2021-08-13 温州医科大学附属第二医院（温州医科大学附属育英儿童医院） 一种基于红细胞膜的超小仿生纳米颗粒制备方法
AU2022257989A1 (en) * 2021-04-13 2023-11-30 Mcmaster University Functionalized biological membranes with modifying protein molecules, and methods of making and uses thereof
CN113181354B (zh) * 2021-04-25 2023-05-26 中国农业科学院兰州兽医研究所 基于树突状细胞的口蹄疫仿生纳米疫苗及其制备方法和应用
CN113133988B (zh) * 2021-04-26 2023-04-07 西南医科大学附属医院 一种红细胞膜仿生修饰的肾靶向纳米载药系统、制备方法及应用
CN113197880B (zh) * 2021-05-07 2021-11-12 皖南医学院第一附属医院（皖南医学院弋矶山医院） 一种巨噬细胞外泌体膜包被仿生纳米颗粒及其制备方法和应用
CN113633625B (zh) * 2021-05-19 2022-12-09 河南大学 一种杂膜负载氧化磷酸化抑制剂的纳米药物及其制备方法
CN113398900B (zh) * 2021-07-14 2023-03-31 广州汇标检测技术中心 一种针对黄曲霉毒素的分子印迹材料及其制备方法和应用
US20230032473A1 (en) * 2021-07-23 2023-02-02 Wisconsin Alumni Research Foundation Nad(h) nanoparticles and methods of use
CN113893229B (zh) * 2021-08-06 2023-09-05 四川省医学科学院·四川省人民医院 一种红细胞膜包裹藤黄酸的仿生纳米颗粒、制备方法及其应用
CN113925836A (zh) * 2021-09-29 2022-01-14 苏州大学 清除rankl的细胞膜包被纳米诱饵、其制备及应用
CN114129536A (zh) * 2021-12-03 2022-03-04 深圳市融创金石科技有限公司 仿生普鲁士蓝复合材料及其制备方法和应用
CN114470223B (zh) * 2022-01-13 2023-09-29 苏州大学 清除促炎因子和抑制t细胞活化的细胞膜包被纳米诱饵及其制备方法与应用
WO2023153832A1 (ko) * 2022-02-14 2023-08-17 가천대학교 산학협력단 병소에 대한 표적능이 강화된 엑토좀-생분해성 고분자 나노입자 복합체 및 그의 제조방법
WO2023161350A1 (en) 2022-02-24 2023-08-31 Io Biotech Aps Nucleotide delivery of cancer therapy
CN114668772B (zh) * 2022-03-15 2024-12-10 温州医科大学附属第二医院（温州医科大学附属育英儿童医院） 负载两性霉素b仿生纳米系统的组合物、制备方法及应用
AU2023269182A1 (en) * 2022-05-09 2024-11-14 Yale University Immunotherapy of skin cancer using mpla-loaded hpg nanoparticles
CN115068606B (zh) * 2022-05-23 2023-05-16 山东大学 一种肿瘤靶向纳米制剂、制备方法及在抗肿瘤药物制备中的应用
CN115227671B (zh) * 2022-07-13 2024-01-19 中山大学附属第一医院 一种药物递送系统及其制备方法和应用
CN115590836B (zh) * 2022-09-27 2024-06-21 浙江大学 一种提高mRNA疫苗诱导免疫应答能力的脂质纳米颗粒及其应用
CN115708864A (zh) * 2022-11-24 2023-02-24 东南大学 血小板硼替佐米的药物组合物、方法及应用
CN116139104A (zh) * 2022-11-29 2023-05-23 深圳先进技术研究院 一种靶向性仿生聚多肽纳米递送载体、纳米核酸递送系统及其制备方法和应用
CN115804762B (zh) * 2022-12-20 2024-05-31 浙江大学 一种巨噬细胞膜包覆的异位子宫内膜靶向纳米粒、制备方法及应用
CN116270525B (zh) * 2023-02-22 2024-12-13 南京华盖制药有限公司 一种用于治疗肺部细菌感染性肺炎的可吸入仿生纳米材料及其制备方法和应用
CN118717701A (zh) * 2023-03-29 2024-10-01 国家纳米科学中心 细菌矿化金属纳米颗粒用于治疗肿瘤
WO2024249782A2 (en) * 2023-06-02 2024-12-05 The Methodist Hospital Biomimetic proteolipid nanovesicles for delivery of nucleic acids
CN116531344A (zh) * 2023-06-07 2023-08-04 重庆医科大学附属儿童医院 一种巨噬细胞膜修饰的纳米颗粒及其制备方法和应用
KR20250000043A (ko) * 2023-06-23 2025-01-02 한양대학교 산학협력단 나노입자, 이의 제조 방법 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물
CN116652180B (zh) * 2023-07-31 2023-09-26 环保桥(湖南)生态环境工程股份有限公司 一种基于零价铁粉的复合颗粒及其制备方法与应用
EP4520345A1 (en) 2023-09-06 2025-03-12 Myneo Nv Product
EP4556028A1 (en) 2023-11-14 2025-05-21 Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie - Hans-Knöll-Institut - Functionalized nanoparticles for viral clearance
CN120053376A (zh) * 2025-01-24 2025-05-30 深圳市龙岗中心医院 用于肿瘤光动力治疗的仿生纳米脂质体及其制备方法、在制备治疗肿瘤的药物中的应用

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59157033A (ja) * 1983-02-28 1984-09-06 Hidetoshi Tsuchida 赤血球ゴ−スト膜フラグメントからなる小胞体の製造方法および小胞体
US4891208A (en) 1985-04-10 1990-01-02 The Liposome Company, Inc. Steroidal liposomes
WO1991002704A1 (en) * 1989-08-18 1991-03-07 Monsanto Company Ferritin analogs
US5643577A (en) * 1990-04-24 1997-07-01 The University Of Newcastle Research Associates Limited Oral vaccine comprising antigen surface-associated with red blood cells
US5612034A (en) * 1990-10-03 1997-03-18 Redcell, Inc. Super-globuling for in vivo extended lifetimes
US5491219A (en) * 1993-06-11 1996-02-13 Protein Magnetics Ferritin with ferrimagnetically ordered ferrite core and method technical field
CA2150617C (en) * 1995-02-07 2001-10-30 Universite Laval Nanoerythrosome as bioactive agent carrier
CA2213906A1 (en) * 1996-09-23 1998-03-23 Dusica Maysinger Pharmaceutical composition and method for neuron rescue in ischemic stroke
US6395029B1 (en) * 1999-01-19 2002-05-28 The Children's Hospital Of Philadelphia Sustained delivery of polyionic bioactive agents
GB0007150D0 (en) * 2000-03-24 2000-05-17 Lamellar Therapeutics Limited Immunotherapeutic methods and compositions
AUPR011700A0 (en) * 2000-09-14 2000-10-05 Austin Research Institute, The Composition comprising immunogenic virus sized particles (VSP)
FR2839260B1 (fr) * 2002-05-03 2005-02-25 Inst Nat Sante Rech Med Microparticules a base d'un materiau bicompatible et biodegradable, supportant des cellules et des substances biologiquement actives
US20040180094A1 (en) * 2003-03-11 2004-09-16 Hemolytics, Inc. Activation agents on the surface of encapsulation vesicles
EP1631264B8 (en) 2003-06-02 2017-05-24 GlaxoSmithKline Biologicals SA Immunogenic compositions based on microparticles comprising adsorbed toxoid and a polysaccharide-containing antigen
WO2006033679A2 (en) * 2004-05-25 2006-03-30 Chimeracore, Inc. Self-assembling nanoparticle drug delivery system
US20070258889A1 (en) * 2005-11-09 2007-11-08 Montana State University Novel nanoparticles and use thereof
MY148405A (en) 2006-03-30 2013-04-30 Glaxosmithkline Biolog Sa Immunogenic composition
US20070243137A1 (en) * 2006-04-18 2007-10-18 Nanoprobes, Inc. Cell and sub-cell methods for imaging and therapy
GB2439747A (en) 2006-07-03 2008-01-09 Uni Degli Studi Di Urbino Carl Delivery of contrasting agents for magnetic resonance imaging
US8465775B2 (en) 2006-07-27 2013-06-18 The University Of North Carolina At Chapel Hill Nanoparticle fabrication methods, systems, and materials for fabricating artificial red blood cells
WO2008150276A2 (en) * 2006-09-26 2008-12-11 The Board Of Regents Of The University Of Texas System Virus coated nanoparticles and uses thereof
RU2345805C1 (ru) 2007-07-04 2009-02-10 Государственное образовательное учреждение высшего профессионального образования "Саратовский государственный университет им. Н.Г. Чернышевского" Способ лазерного фототермолиза серповидно-клеточных эритроцитов
US8329161B2 (en) * 2008-05-01 2012-12-11 National Health Research Institutes Red blood cell-derived vesicles as a nanoparticle drug delivery system
JP5721620B2 (ja) 2008-05-02 2015-05-20 キャンサー・リサーチ・テクノロジー・リミテッドＣａｎｃｅｒ Ｒｅｓｅａｒｃｈ Ｔｅｃｈｎｏｌｏｇｙ Ｌｉｍｉｔｅｄ 免疫応答を刺激するための作製物および方法
CN101306196B (zh) 2008-07-03 2011-05-11 中国科学院长春应用化学研究所 一种生物降解的键合了血红蛋白分子的纳米粒子及制法
US20110262415A1 (en) * 2008-12-21 2011-10-27 Cnr - Consiglio Nazionale Delle Ricerche Erythrocyte-based delivery system, method of preparation and uses thereof
JP5667180B2 (ja) * 2009-07-01 2015-02-12 イオン メディックス インコーポレイテッド 哺乳類の有核細胞に由来するマイクロベシクル及びその用途
CN101735613B (zh) 2009-12-08 2012-09-05 四川大学 一种聚合物多孔纳米微球及其制备方法
WO2011116237A1 (en) * 2010-03-17 2011-09-22 Board Of Regents Of The University Of Texas System Universal cell-directed theranostics
AU2011258165B2 (en) * 2010-05-26 2016-11-17 Selecta Biosciences, Inc. Dose selection of adjuvanted synthetic nanocarriers
GB201011968D0 (en) 2010-07-16 2010-09-01 Secr Defence Toxoiding method
CN101926984B (zh) * 2010-08-05 2012-09-05 中国人民解放军第四军医大学 一种人工纳米红细胞的制备方法
CN101934080B (zh) * 2010-09-08 2012-05-23 西北大学 一种利用静电自组装涂层改善材料血液相容性的方法
AU2012249474A1 (en) * 2011-04-28 2013-11-07 Stc.Unm Porous nanoparticle-supported lipid bilayers (protocells) for targeted delivery and methods of using same
CN103857387B (zh) 2011-06-02 2017-03-15 加利福尼亚大学董事会 膜包封的纳米颗粒及使用方法
WO2015021390A2 (en) 2013-08-08 2015-02-12 The Regents Of The University Of California Nanoparticles leverage biological membranes to target pathogens for disease treatment and diagnosis
WO2015084677A1 (en) 2013-12-02 2015-06-11 Arytha Biosciences, Llc Toxoid preparation and uses thereof
WO2015143295A2 (en) * 2014-03-20 2015-09-24 The Regents Of The University Of California Hydrogel compositions containing toxin-absorbing or binding nanoparticles and uses thereof
US11110127B2 (en) 2014-06-02 2021-09-07 Cellics Therapeutics, Inc. Use of nanoparticles coated with red blood cell membranes to treat hemolytic diseases and disorders
US12285472B2 (en) * 2014-08-20 2025-04-29 The Regents Of The University Of California Self-antigen displaying nanoparticles targeting auto-reactive immune factors and uses thereof
WO2016109306A1 (en) 2015-01-02 2016-07-07 Cellics Therapeutics, Inc. Use of nanoparticles coated with red blood cell membranes to enable blood transfusion
WO2016153979A1 (en) * 2015-03-20 2016-09-29 The Regents Of The University Of California Modulating antibacterial immunity via bacterial membrane-coated nanoparticles
CN107530285B (zh) * 2015-04-29 2021-07-27 加利福尼亚大学董事会 使用纳米粒子解毒
US11224577B2 (en) * 2015-06-19 2022-01-18 The Regents Of The University Of California Treating infection by a platelet-targeting microbe using nanoparticles
WO2016205010A1 (en) 2015-06-19 2016-12-22 The Regents Of The University Of California Treating vasculature related diseases or disorders using nanoparticles
WO2017087897A1 (en) * 2015-11-18 2017-05-26 Arytha Biosciences, Llc Processes and systems for preparing cellular or viral membranes and nanoparticles
WO2017120342A1 (en) * 2016-01-08 2017-07-13 The Regents Of The University Of California Cellular or viral membrane coated nanostructures and uses thereof

Also Published As

Publication number Publication date
CN103857387B (zh) 2017-03-15
TW201311297A (zh) 2013-03-16
ES2685333T3 (es) 2018-10-08
EP3412282A1 (en) 2018-12-12
EP3412282C0 (en) 2024-10-09
DK2714017T3 (en) 2018-09-03
CN107115314A (zh) 2017-09-01
HK1243002A1 (zh) 2018-07-06
JP2014518200A (ja) 2014-07-28
US12097290B2 (en) 2024-09-24
TWI668019B (zh) 2019-08-11
CA2873404A1 (en) 2013-04-11
EP2714017A2 (en) 2014-04-09
US20130337066A1 (en) 2013-12-19
TW201729799A (zh) 2017-09-01
US20250017860A1 (en) 2025-01-16
HK1197016A1 (en) 2015-01-02
US20250049716A1 (en) 2025-02-13
CN103857387A (zh) 2014-06-11
US20240252438A1 (en) 2024-08-01
CN107115314B (zh) 2022-04-29
TWI638667B (zh) 2018-10-21
WO2013052167A3 (en) 2014-05-01
JP6100762B2 (ja) 2017-03-22
WO2013052167A2 (en) 2013-04-11
US20250049715A1 (en) 2025-02-13
EP3412282B1 (en) 2024-10-09
EP2714017A4 (en) 2015-06-03
EP2714017B1 (en) 2018-08-01

Similar Documents

Publication Publication Date Title
US20250049716A1 (en) Membrane Encapsulated Nanoparticles and Method of Use
US10363226B2 (en) Platelet membrane-coated drug delivery system
Zhu et al. Applications of nanomaterials as vaccine adjuvants
CA2800497C (en) Methods for preparing ratiometric combinatorial nanoparticules
KR102557336B1 (ko) 혈소판 조성물 및 치료제의 전달 방법
US20160151482A1 (en) Mesoporous alum nanoparticles as a universal platform for antigen adsorption, presentation, and delivery
WO2018089688A1 (en) Restoration of tumor suppression using mrna-based delivery system
HK40001508A (en) Membrane encapsulated nanoparticles and method of use
HK1197016B (en) Membrane encapsulated nanoparticles and method of use
HK1243002B (en) Membrane encapsulated nanoparticles and method of use
Singh et al. Cutting edge targeting strategies utilizing nanotechnology in breast cancer therapy
EP4583848A2 (en) Layer-by-layer delivery of active agents
Thamphiwatana Antimicrobial Nanotherapeutics Against Helicobacter pylori Infection
Yanasarn Lipid Based Nanocarriers for Chemotherapeutic Drug Docetaxel and Vaccine Delivery

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20170407

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 13TH ANNIV.) - STANDARD

Year of fee payment: 13

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250520

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250520